Introduction {#s1}
============

Regulation of animal growth and development in response to nutritional cues is an intensely studied problem ([@bib27]; [@bib82]). In animals, nutrient signals are perceived in specialized tissues and are then communicated to all other tissues to coordinate growth and development. The target of rapamycin (TOR) complexes (TORC1 and TORC2) are known to function in sensing various nutrient signals ([@bib46]; [@bib39]; [@bib81]), and their roles are connected to growth, metabolism, stress responses, and cancers ([@bib24]; [@bib26]; [@bib29]). While amino acids, energy, and growth factors have been described as nutrient inputs to TOR complexes, roles of lipid molecules as signals to these systems in controlling postembryonic growth and development were not known. Clearly, it is also essential to use whole-animal models to investigate how different signaling systems in different tissues interact to specify decisions regarding postembryonic development and behaviors.

In *Caenorhabditis elegans*, the first larval stage has been established as a model system for the study of animal growth and development in response to food availability. When hatched in food-free surroundings, this nematode enters a quiescent state, termed L1 diapause ([@bib30]; [@bib52]; [@bib5]). An insulin/IGF-1 receptor signaling (IIS) pathway plays a critical role in the induction of L1 diapause and survival of the developmentally arrested animals ([@bib19]; [@bib5]; [@bib37]; [@bib40]; [@bib31]; [@bib72]). Moreover, TOR complexes have also been indicated to play prominent roles in regulating postembryonic growth and lifespan in *C. elegans* ([@bib76]; [@bib74]; [@bib24]; [@bib28]; [@bib45]).

Monomethyl branched-chain fatty acids (mmBCFAs) are widely present in bacteria, plants, and animals, including humans ([@bib57]; [@bib65]). In mammals, mmBCFAs are derived from branched-chain amino acids (BCAAs) ([@bib50]; [@bib60]), although the remainder of the de novo pathway has not been delineated. The physiological roles of these FA variants are essentially unknown, even though they were found to be present at very high levels in certain tissues ([@bib57]; [@bib65]). In *C. elegans*, readily detectable mmBCFAs C15ISO and C17ISO are synthesized from the BCAA leucine ([@bib36]). The key enzymes in this de novo synthesis pathway, including the branched-chain ketoacid dehydrogenase complex (BCKDC), an FA elongase (ELO-5), and an acyl CoA synthetase (ACS-1), are evolutionarily conserved ([@bib36], [@bib37]).

We have previously shown that newly hatched *C. elegans* that are deficient for mmBCFAs cannot initiate postembryonic growth and development, and instead enter L1 diapause. Further genetic analysis suggested that this developmental arrest is independent of the IIS pathway ([@bib36], [@bib37]). It was not clear whether the essential roles of mmBCFAs and their derived lipids were due to structural requirements for animal development, as was suggested by other studies, or due to regulatory functions specific to cellular signaling processes. Testing these hypotheses using model organisms is highly significant because roles of fatty acids and lipids function as nutrient signals for postembryonic development are in general poorly understood.

In this study, we discovered that (1) an mmBCFA-derived glucosylceramide (d17iso-GlcCer) mediates the function of mmBCFAs in promoting postembryonic growth and development and (2) d17iso-GlcCer acts through a signaling system that includes the NPRL-2/NPRL-3 protein complex (negative factor) and TORC1 (positive factor) to promote postembryonic development.

Results {#s2}
=======

A sphingolipid composed of a mmBCFA-derived long chain base mediates the essential role of mmBCFAs in the initiation of postembryonic growth and development {#s2-1}
------------------------------------------------------------------------------------------------------------------------------------------------------------

*elo-5* loss-of-function mutants (termed *elo-5(−)* hereafter) are deficient for mmBCFAs and are developmentally arrested at the early L1 stage. This phenotype is completely rescued by dietary supplementation of mmBCFAs ([@bib36], [@bib37]). We found that in mmBCFA-deficient *elo-5(−)* larvae, the amount of mmBCFA-containing sphingolipids were dramatically reduced and thus asked if this mmBCFA function is mediated by a sphingolipid.

Sphingolipids are a class of well-known bioactive lipids ([@bib23]) that are composed of an aliphatic amino alcohol backbone called the sphingoid base or long chain base (LCB), and usually an N-acylated fatty acid (FA) side chain ([Figure 1A](#fig1){ref-type="fig"}). In *C. elegans*, both the LCB and the FA side chain may derive from mmBCFAs, such as C15ISO and C17ISO ([@bib11]; [@bib20]; [Figure 1A](#fig1){ref-type="fig"}). In this study, a sphingolipid with a mmBCFA-derived LCB is termed d17iso-sphingolipid, whereas a sphingolipid with a C17ISO-derived FA side chain and a straight LCB is termed c17iso-sphingolipid. The 'd' and 'c' refer to carbon atoms on the LCB and FA chain, respectively.10.7554/eLife.00429.003Figure 1.Iso-branched d17iso-sphinganine rescues elo-5(-) L1 arrest.(**A**) Sphingolipid biogenesis pathway in *C. elegans*, including the catalytic enzymes (blue) and corresponding genes (red) used in this study. Molecular structures in green and in light blue indicate the long chain base and side chain fatty acid, respectively. (**B**) Summary of growth phenotype of various mutants with indicated lipid supplementations. *elo-5(gk208)*, *cgt-1(tm1027)*, and *cgt-3(tm504)* were the alleles of the (−) mutants. LCB: long chain base; SPA: sphinganine. See [Supplementary file 1](#SD1-data){ref-type="supplementary-material"} for numerical data or more detailed description of the phenotypes. (**C**) Mass spectrometry of iso-branched d17iso-sphinganine (d17iso-SPA) isolated from the bacteria *S. spiritivorum*. The major peak (*m/z* = 288.4) corresponds to d17iso-SPA in each panel. The lower panel shows fragmentation of d17iso-SPA by MS-MS scan. The fragment peaks are labeled with the name of lost residues. (**D**) d17iso-SPA rescues *elo*-5*(−)* animals more efficiently than C15ISO and C17ISO. Error bar, SD. (**E**) Gas chromatography of methyl-esterified fatty acid extracts from rescued *elo*-5*(−)* animals fed with d17iso-SPA. Low concentration of d17iso-SPA (second and third panels) supplement did not restore C15iso or C17iso fatty acid levels.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.003](10.7554/eLife.00429.003)

We then examined if dietary supplementation with either of these two types of sphingolipids could substitute for mmBCFAs to rescue *elo-5(−)* animals from L1 arrest. Because the d17iso-LCB was not commercially available, we purified d17iso-sphinganine (d17iso-SPA; [Figure 1A](#fig1){ref-type="fig"}) from a d17iso-sphingolipid producing bacteria *S. spiritivorum* ([@bib78]) using mass spectrometry analysis. This purified d17iso-SPA fraction, but not a chemically synthesized c17iso-sphingolipid with a straight-chain d18:1-LCB or a straight-chain LCB d16-SPA, was found to be sufficient to overcome *elo-5(−)* L1 arrest ([Figure 1B,C](#fig1){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplement-material"}). Additionally, efficient rescue was also achieved with a custom synthesized d17iso-SPA ([Figure 1D](#fig1){ref-type="fig"}). Therefore, d17iso-sphingolipid is sufficient to promote the postembryonic growth and development of mmBCFA-deficient animals.

We then carried out further tests to confirm that this rescue effect of d17iso-SPA supplementation resulted from the function of this metabolite itself, but not from its catabolic conversion back to C15ISO or C17ISO. First, we fed *elo-5(−)* larvae with various quantities of C15ISO, C17ISO, or d17iso-SPA. We observed that d17iso-SPA suppressed the L1 arrest at a much lower concentration than C15ISO or C17ISO ([Figure 1D](#fig1){ref-type="fig"}). Second, we observed that the low concentrations of d17iso-SPA suppressed the L1 arrest without restoring mmBCFA levels ([Figure 1E](#fig1){ref-type="fig"}). Finally, we found that supplementation with d17iso-SPA, but not mmBCFAs, also suppressed the L1 arrest phenotype caused by feeding RNAi of *sptl-1*, a gene encoding a serine palmitoyltransferase homolog in *C. elegans* required for d17iso-SPA biosynthesis ([Figure 1A,B](#fig1){ref-type="fig"}; [@bib69]). We thus conclude that mmBCFAs promote postembryonic development through d17iso-SPA.

This growth-promoting function of d17iso-SPA may be mediated by a more complex sphingolipid derived from it. Because it is technically difficult to purify or synthesize sphingolipids of more complex structure (e.g., glucosylceramide \[GlcCer\]) and directly test their effect by dietary supplementation, we examined additional enzymes involved in sphingolipid synthesis. Specifically, *fath-1(C25A1.5)* encodes a homolog of mammalian fatty acid 2-hydrolase (FA2H) responsible for the synthesis of the FA side chain of ceramides, whereas *cgt-1* and *cgt-3* encode two ceramide glucosyltransferases that glucosylate ceramides to GlcCer ([Figure 1A](#fig1){ref-type="fig"}). Both *fath-1(RNAi)-*treated animals ([Figure 1B](#fig1){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplement-material"}) and the *cgt-1(−);cgt-3(−)* double mutant ([@bib47]) cause larval arrest. We found the arrest under either condition could not be overcome by feeding d17iso-SPA ([Figure 1B](#fig1){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplement-material"}). Disrupting the function of glycosyltransferases that further modify GlcCer does not cause larval arrest ([@bib21]). These results suggest that d17iso-glucosylceramide (d17iso-GlcCer) ([Figure 1A](#fig1){ref-type="fig"}) may be the lipid molecule that mediates the role of mmBCFAs and d17iso-SPA in promoting postembryonic growth and development in *C. elegans*.

Mutation *ku540* permits mmBCFA-depleted *C. elegans* to bypass L1 arrest and propagate continuously {#s2-2}
----------------------------------------------------------------------------------------------------

d17iso-sphingolipid may play either a structural or regulatory role for the initiation of postembryonic development. If it is the latter, the requirement of d17iso-sphingolipid for postembryonic development might be bypassed by genetically activating the downstream regulatory pathway. To test this possibility and identify the mechanism, we performed a genetic screen, modified from a previous screen ([@bib69]), for mutations that could suppress the L1 arrest of *elo-5(−)* mutants ([Figure 2A](#fig2){ref-type="fig"}). Among four suppressors identified in this screen, and the *tat-2* mutations from a previous *elo-5(−)* suppressor screen ([@bib69]), *ku540* was the only mutation that rescued *elo-5(−)* larvae to adults and permitted growth for more than one generation without mmBCFA supplementation or restoration of mmBCFA synthesis ([Figure 2B--E](#fig2){ref-type="fig"}; see 'Materials and methods'). In fact, *elo-5(−);ku540* homozygous animals could propagate continuously, even though they displayed slow growth, smaller body size, and smaller brood size ([Figure 2C](#fig2){ref-type="fig"}).10.7554/eLife.00429.004Figure 2.*ku540* mutant suppresses L1 arrest of mmBCFA and sphingolipid biosynthetic mutants without restoring the levels of mmBCFAs.(**A**) Screening strategy to isolate *elo*-5*(−)* suppressors. Green-colored *C. elegans* carry the extrachromosomal array containing copies of the *elo-5(+), sur-5-gfp*, and *rol-6(dn)* genes. (**B**) Percentages of animals reaching adulthood (bypass L1 arrest) when fed with/without C17ISO supplement. *elo-5(−);ku540* mutant animals reach adulthood without C17ISO supplement. Error bar, SD. (**C**) Images showing that *elo*-*5(−)* animals arrested at L1 and *elo-5(−);ku540* animals reached adulthood. (**D**) Mass spectrometry by precursor scan *m/z* = −241.2 showing no detectable C15FA-containing lipids in *elo-5(−);ku540* animals. Numeric data for the levels of PA and PE are shown in [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}. (**E**) Bar graph of relative FA composition by gas chromatography (GC) of methyl-esterified fatty acid extracts. These data indicate no detectable C15ISO or C17ISO was restored in *elo-5(−) ku540* animals. GC graph is shown in [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}. (**F**) and (**G**) Mass spectrometry of d17iso-ceramide--containing lipids by precursor scan *m/z* = +250.3, and d16-ceramide--containing lipids by precursor scan m/z = +236.3 (**F**). d17iso-ceramides and d17iso-glucosylceramides are detectable in wild-type but not *elo-5(−);ku540* animals (**G**). In contrast, d16-ceramides and d16-glucosylceramides are present in *elo-5(−);ku540,* but not wild-type, animals. Numeric data for relevant peaks are shown in [Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}. (**H**) and (**I**) Percentages of animals of the indicated genotypes and treatment that reached adulthood. Error bar, SD. (**H**) The addition of *ku540* dramatically suppressed the L1 arrest phenotype of *cgt-1(−);cgt-3(RNAi)* with and without the C17ISO supplement. The inclusion of *elo*-5*(−)* was due to its close linkage with *ku540*. When C17ISO was added to remove the negative effect of *elo*-5*(−),* about 90% of *elo-5(−);ku540; cgt-1(−);cgt-3(RNAi)* animals reached adulthood. C17ISO itself does not rescue the phenotype. (**I**). *ku540* suppressed the L1 arrest phenotype the *cgt-1(−);cgt-3 (−)* double mutants (83.4%, n = 126). In this particular test, *elo-5(−) ku540;cgt-1(−);cgt-3(−)* homozygous animals were the progeny of *elo-5(−/+) ku540(−/+);cgt-1(−/+);cgt-3(−)* heterozygous mothers, and the presented data were obtained after normalizing against heterozygous populations (see 'Materials and methods'). In all the other tests shown in [Figure 2](#fig2){ref-type="fig"}, *elo-5(−) ku540* homozygous animals were the progeny of homozygous mothers.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.004](10.7554/eLife.00429.004)10.7554/eLife.00429.005Figure 2---figure supplement 1.Quantification of GC and mass spectrometry analyses of *elo-5(−) ku540* animals.(**A**) Tables show relative intensities of the five strongest signals by mass spectrometry precursor scan (*m/z* = −241.2) in wild-type animals (second right column) and their normalized relative intensities in *elo-5(−) ku540* animals (right column). The low intensities of these lipids in *elo-5(−) ku540* animals indicate that the C15ISO mmBCFA level was not restored *elo-5(−) ku540* animals. (**B**) Gas chromatography of methyl-esterified fatty acid extracts showing no detectable C15ISO or C17ISO in *elo-5(−) ku540* animals. (**C**) Table shows relative intensities of normal d17iso-sphingolipid by mass spectrometry precursor scan (*m/z* = +250.3) in wild-type animals (second right column) and their normalized relative intensities in *elo-5(−) ku540* animals (right column). The low intensities of these lipids in *elo-5(−) ku540* animals indicate that the d17iso-sphingolipid level was not restored *elo-5(−) ku540* animals. (**D**) Table shows relative intensities of abnormal d16-sphingolipid by mass spectrometry precursor scan (*m/z* = +238.3) in *elo-5(−) ku540* animals (second right column). These sphingolipids are not present in wild-type animals (right column).**DOI:** [http://dx.doi.org/10.7554/eLife.00429.005](10.7554/eLife.00429.005)10.7554/eLife.00429.006Figure 2---figure supplement 2.Suppression of *fath-1(−)* by *nprl-3(ku540)*.Microscopic images showing that *nprl-3(ku540)* suppresses the L1 arrest phenotype of *fath-1 (injection RNAi)* with or without C17ISO supplementation.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.006](10.7554/eLife.00429.006)

Mass spectrometry (MS) and gas chromatography (GC) analyses indicated that *elo-5(−)*;*ku540* did not restore mmBCFA levels, and consequently the levels of d17iso-sphingolipids ([Figure 2D--G](#fig2){ref-type="fig"}). *elo-5(−);ku540* animals had no detectable C15ISO-containing or C17ISO-containing lipids ([Figure 2D,E](#fig2 fig2){ref-type="fig"}, [Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). In contrast to wild type animals, *elo-5(-);ku540* animals had ceramides and glucosylceramides containing straight chain d16LCB rather than d17isoLCB ([Figure 2F,G](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}), which is similar to the *elo-5(−)* single mutant ([@bib17]). These data indicated that the suppression of L1 arrest by the *ku540* mutation is neither due to a change in mmBCFA nor the metabolism of the derived sphingolipids. Therefore, our data suggest that *ku540* renders mmBCFAs nonessential for *C. elegans* development.

Mutation *ku540* also permits animals to bypass the requirement for d17iso-GlcCer in postembryonic development {#s2-3}
--------------------------------------------------------------------------------------------------------------

The above results suggested that *ku540* might modify a signaling pathway downstream of d17iso-sphingolipids. If so, *ku540* should also suppress mutations disrupting the biosynthesis of this sphingolipid. This question was addressed by the following tests. As shown above, RNAi of *fath-1,* or mutating both *cgt-*1 and *cgt-3,* caused larval arrest that could not be rescued by feeding with either mmBCFAs or d17iso-SPA ([Figure 1A,B](#fig1){ref-type="fig"}). We found that the L1 arrest under both conditions, just like the arrest caused by *elo-5(−)*, was effectively suppressed by *ku540* ([Figure 2H,I](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). These results provided strong evidence that d17iso-GlcCer mediated the roles of mmBCFAs and d17iso-SPA in postembryonic development. Taken together, our biochemical and genetic data indicate that *ku540* bypasses the requirement of mmBCFAs and d17iso-GlcCer in development and does so by modifying a regulatory function downstream of d17iso-GlcCer.

*ku540* is a loss-of-function mutation of *nprl-3* that may function with *nprl-2* {#s2-4}
----------------------------------------------------------------------------------

We cloned the gene containing the *ku540* mutation by genetic mapping and whole-genome sequencing ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The gene was annotated as F35H10.7 ([wormbase.org](http://wormbase.org)) that encodes a protein structurally conserved from budding yeast (NPR3, Nitrogen Permease Regulator 3) to humans (NPRL-3, Nitrogen Permease Regulator Like 3; [Figure 3B](#fig3){ref-type="fig"}). We named the gene *nprl-3* (NPRL-3 for protein). *nprl-3(ku540)* is a C-T substitution that changes a conserved proline to serine ([Figure 3A](#fig3){ref-type="fig"}). RNAi of *nprl-3* by dsRNA injection also rescued the L1 arrest of *elo-5(−)* and *cgt-1(−)*;*cgt-3(−)* animals ([Figure 3C](#fig3){ref-type="fig"}), indicating that *ku540* is likely a partial loss-of-function or reduction-of-function mutation. A transcriptional GFP fusion transgene (*nprl-3::GFP*) was observed to express ubiquitously throughout development and adulthood ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).10.7554/eLife.00429.007Figure 3.*ku540* is a loss-of-function missense mutation of *nprl-3*.(**A**) Predicted structure and position of the *ku540* mutation in the *nprl-3* gene (F35H10.7). (**B**) Abbreviated alignment of *C. elegans* NPRL-3 with its orthologs in other organisms. (**C**) *C. elegans* images showing *nprl-3(RNAi)* mimics the effect of the *ku540* mutation in rescuing the L1 arrest phenotype caused by blocking mmBCFA or glucosyl-ceramide biosynthesis. *nprl-3* dsRNA injection rescued 61.0% of *elo-5(−)* (n = 123) and 6.8% of *cgt-1(−) cgt-3(−)* (n = 71) animals to or beyond L3 stage. *nprl-2* dsRNA injection also rescued 42.4% of *elo-5(−)* animals to or beyond L3 stage (n = 128). All data have been normalized to heterozygous populations (see 'Materials and methods').**DOI:** [http://dx.doi.org/10.7554/eLife.00429.007](10.7554/eLife.00429.007)10.7554/eLife.00429.008Figure 3---figure supplement 1.Mapping and expression of *nprl-3*.(**A**) A simplified diagram of the mapping process. *ku540* is genetically linked to the E03H12 SNP marker on chromosome IV (upper section). Further three-point mapping narrowed the *ku540* locus to near *unc-24*, by visible markers (red) and by physical mutations (blue) found by genomic deep sequencing (middle section). The three candidate gene mutations resulting in amino acid changes are shown (lower section). (**B**) DIC and fluorescence images showing two representative animals carrying a *nprl-3* promoter::GFP transgene. The head is indicated by a black arrow. GFP is visible in most tissues with stronger expression seen in the head and tail regions.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.008](10.7554/eLife.00429.008)

In *Saccharomyces cerevisiae*, NPR3 was shown to form a heterodimer with NPR2. Mutations in both proteins cause multiple growth defects when cells were cultured in low-quality amino acid conditions ([@bib56]). We found that RNAi by dsRNA injection of the *C. elegans* NPR2 homolog *nprl-2* (F49E8.1) also suppressed the developmental arrest of *elo-5(−)* larvae ([Figure 3C](#fig3){ref-type="fig"}). This suggested that NPRL-2 and NPRL-3 in *C. elegans* may also function in a complex to negatively impact mmBCFA/d17iso-GlcCer-mediated L1 growth.

NPRL-3 regulates d17iso-GlcCer function in L1 growth by repressing TORC1 activity {#s2-5}
---------------------------------------------------------------------------------

The NPR2/3 complex was proposed to be a negative regulator of the TOR pathway in *S. cerevisiae*, based on the observations that mutations in these two genes caused growth defects in an amino acid scarce environment and that the defects could be effectively suppressed by blocking the TOR pathway ([@bib56]). We thus explored the possibility that TOR Complex 1 (TORC1) is also the downstream target of NPRL2/3 in growth regulation in *C. elegans* and that *nprl-3(ku540)* alleviates d17iso-GlcCer deficiency-induced growth arrest by activating the TORC1 pathway.

We reasoned that if reducing *nprl-2/3* activity rescued *elo*-5*(−)* L1 growth by up-regulating the TORC1 pathway in *C. elegans*, then reducing, but not eliminating, TORC1 activity may reverse the rescue effects of *nprl-3(ku540)* on *elo-5(−)* mutant background. *Caenorhabditis elegans* has orthologs of key components of mammalian TORC1, including regulatory elements *raga*-*1* (RagA) and *rheb*-*1* (Rheb) ([@bib44]; [@bib67]). Feeding RNAi of *raga-1* and *rheb-1* have been shown to be specific and effective to reduce, but not eliminate, TORC1 function ([@bib25]; [@bib74]; [@bib41]; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}; see 'Materials and methods'). We thus tested the effect of *raga-1(RNAi)* and *rheb-1(RNAi)* on *elo-5(−) nprl-3(ku540)* mutants*.*

While *nprl-3(ku540)* effectively suppressed the L1 arrest phenotype of *elo-5(−)*, the suppression dramatically decreased when *raga-1(RNAi)* or *rheb-1(RNAi)* were applied to the *elo-5(−) nprl-3(ku540)* double mutant ([Table 1](#tbl1){ref-type="table"}). This indicates that the rescue effect of *nprl-3(ku540)* on *elo-5(−)* depends on intact TORC1 activity.10.7554/eLife.00429.009Table 1.Intact TORC1 function is necessary for mmBCFA-mediated growth regulation**DOI:** [http://dx.doi.org/10.7554/eLife.00429.009](10.7554/eLife.00429.009)GenotypeRNAiDietary C17ISONormalized % of F1 reached adulthoodNp*elo-5(−)*Vector−0208*elo-5(−)*Vector+86.92050*elo-5(−) nprl-3(−)*Vector−71.569*elo-5(−) nprl-3(−)*Vector+111.51030.24*elo-5(−) nprl-3(−)raga-1 (a)*−35.556*elo-5(−) nprl-3(−)raga-1 (a)*+102.5830.031*elo-5(−) nprl-3(−)raga-1 (b)*−25.5214*elo-5(−) nprl-3(−)raga-1 (b)*+88.02790.00001*elo-5(−) nprl-3(−)rheb-1 (a)*−14.2351*elo-5(−) nprl-3(−)rheb-1 (a)*+64.65260.0000001*elo-5(−) nprl-3(−)rheb-1 (b)*−32.5201*elo-5(−) nprl-3(−)rheb-1 (b)*+86.01160.0037*elo-5(−) nprl-3(−)rsks-1 (a)*−15.068*elo-5(−) nprl-3(−)rsks-1 (a)*+72.5830.022*elo-5(−) nprl-3(−)rsks-1 (b)*−19.0183*elo-5(−) nprl-3(−)rsks-1 (b)*+61.01800.0034*elo-5(−) nprl-3(−)ife-2 (a)*−10.5144*elo-5(−) nprl-3(−)ife-2 (a)*+71.5490.003*elo-5(−) nprl-3(−)ife-2 (b)*−0103*elo-5(−) nprl-3(−)ife-2 (b)*+103.51500*elo-5(−) nprl-3(−)let-363*−0\>100*elo-5(−) nprl-3(−)let-363*+0\>100NA[^1]

We carried out further analyses by repeating the above tests in the presence of dietary C17ISO that rescues the defects of *elo-5(−)*. We found that the effects of *raga-1(RNAi)* and *rheb-1(RNAi)* in the above tests were essentially eliminated by C17ISO supplementation ([Table 1](#tbl1){ref-type="table"}). This result further indicates that the reversal of the *nprl-3(ku540)* suppression by *raga-1(RNAi)* or *rheb-1(RNAi)* depends on mmBCFA deficiency. In other words, reducing, but not eliminating, TORC1 activity neutralized the effect of *nprl-3(ku540)* and restored the L1 arrest phenotype of *elo-5(−)*.

To further examine whether the rescuing effect of *nprl-3(ku540)* on *elo-5(−)* L1 arrest required the canonical activity of TORC1, we used RNAi to knock down *C. elegans* orthologs of *elf4E* (*ife-2*) and *p70S6K(rsks-1)*, two well-known downstream targets of TORC1 ([@bib44]; [@bib74]; [@bib1]; [@bib70]). We found that *elo-5(−) nprl-3(ku540)* animals treated with *ife-2(RNAi)* or *rsks-1(RNAi),* with or without C17ISO supplement, yielded results similar to those obtained with *raga-1(RNAi)* and *rheb-1(RNAi)* ([Table 1](#tbl1){ref-type="table"}). Taken together, these results indicate that TORC1 acts downstream of d17iso-GlcCer and is negatively regulated by NPRL-3*.*

The *let-363/TOR(−)* mutations cause late larval arrest and other severe defects ([@bib44]), but injection RNAi causes an early embryonic lethal phenotype ([@bib71]), indicating that LET-363/TOR, a key component of both TORC1 and TORC2, plays critical regulatory roles in a broad range of developmental stages and a maternal effect largely masks its roles in earlier stages, including its likely functions during L1 growth. The defects caused by feeding RNAi of *let-363/TOR* ([@bib44]) are more severe than that by feeding RNAi of other TORC1 components, described above. *elo-5(−) nprl-3(−)*;*let-363(RNAi)* animals displayed pleiotropic phenotypes that could not be rescued by C17ISO supplement ([Table 1](#tbl1){ref-type="table"}), which is consistent with TORC1 acting downstream of ELO-5.

Hyperactivation of TORC1 bypasses mmBCFA deficiency--induced L1 arrest {#s2-6}
----------------------------------------------------------------------

If d17iso-GlcCer mainly acts through TORC1 for the growth regulation function, constitutive activation of TORC1 should be sufficient to overcome the L1 arrest of *elo*-5*(−)* animals, mimicking the effect of *nprl-3(ku540)*. We used three different established methods to test this possibility. We first followed the scheme by [@bib66], in which fusion of one of the TOR binding partners, Raptor, with a C-terminal lysosome localization signal from Rap-1 can localize mTOR to the lysosome and thus constitutively activate the TOR pathway. Both Rap-1 and Raptor proteins are highly conserved in *C. elegans* (encoded by *rap-1* and *daf-15*; [@bib44]; [@bib62]). We fused a 22-amino acid fragment of the C-terminal end of *rap-1* to the C-terminal end of *daf-15* and named it *daf-15::rap-1(22)*. We found that 56.0% of *elo-5(−)* mutants carrying *daf-15::rap-1(22)* bypassed L1 arrest and reached L3 to adult stage (n = 161; normalized against *elo-5(−/+)* heterozygotes containing the transgene; [Figure 4A,B](#fig4){ref-type="fig"}). This indicates that hyperactivation of TORC1 was sufficient to support L1 growth in mmBCFA-depleted animals.10.7554/eLife.00429.010Figure 4.TORC1 activation is sufficient for mmBCFAs-mediated growth regulation.(**A**) Representative florescent images showing that *elo-5(−)* animals with each of four RFP-marked transgenes, which constitutively activated TORC1, bypass L1 arrest to reach beyond L3 stage (statistical data are described in the text and [Figure 4B](#fig4){ref-type="fig"}). The *rpl-28* promoter drives ubiquitous expression, whereas the *ges-1* promoter drives the expression specifically in the intestine ([@bib15]). Arrow in the upper left panel marks an arrested L1. (**B**) Percentage of homozygous *elo-5(−)* animals carrying the *daf-15::rap-1(22)* transgene reached L3-adult stages (n = 161). The data were normalized against that of *elo-5(−/+)* heterozygous animals. Error bar, SD. (**C**). Immunofluorescence images showing FIB-1 expression and localization in intestinal cells of L3 larvae. DAPI-stained nuclei are blue. Green fluorescence indicates the staining of antibody against FIB-1. FIB-1 localization in the nucleoli is largely abolished in *elo-5(−)* animals and restored by the *nprl-3(−)* mutation (the percentages of condensed nucleoli localization for the three genotypes from top to bottom are 95% \[n=42\], 24% \[n=112\] and 93% \[n=68\]). (**D**) A model for the regulation of postembryonic growth and development by mmBCFAs and GlcCer.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.010](10.7554/eLife.00429.010)10.7554/eLife.00429.011Figure 4---figure supplement 1.Microscopic images of *C. elegans* with *raga-1(RNAi)* treatment.Animals without C17ISO supplement were developmentally arrested at L1 stage (arrows). Animals with C17ISO supplement reached adulthood (arrowhead), suggesting that the arrest depends on mmBCFA deficiency and is not caused by RNAi itself.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.011](10.7554/eLife.00429.011)10.7554/eLife.00429.012Figure 4---figure supplement 2.Leucine could not promote postembryonic development independent of the mmBCFA/d17isoGlcCer/TORC1 pathway.Normalized percentages of *elo-5(−)* animals that reached adulthood on various supplements. While 1 mM C17ISO could suppress the L1 arrest of *elo-5(−)*, 10 mM leucine could not. Error bar: SD.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.012](10.7554/eLife.00429.012)10.7554/eLife.00429.013Figure 4---figure supplement 3.mmBCFA/GlcCer/TORC1 pathway is independent of the DAF-7/TGF-β pathway.(**A**) Cartoon illustration of a simplified DAF-7/TGF-β pathway in *C. elegans*. Mutations in *daf-3*, *daf-5*, or *bra-1* have been shown to cause constitutive activity of the TGF-β pathway and suppress dauer formation ([@bib61]). (**B**) Percentages of animals of the indicated genotypes that reached adulthood on *elo-5 (RNAi)* plates. Mutation in none of these negative regulators of the *daf-7* pathway permitted the *elo-5(RNAi)*--treated animals to bypass L1 arrest, suggesting that the TGF-β pathway does not act downstream of mmBCFAs. (**C**) Percentages of *daf-7(−)* animals that exited dauer stage to reach adulthood on indicated RNAi plates. *elo-5(RNAi)* enhanced the constitutive dauer formation phenotype of a *daf-7(−)* mutant. (**D**) Percentages of *daf-7(−)* animals that exited dauer stage to reach adulthood on various branched lipid supplements. Neither C17ISO nor d17iso-SPA could suppress the constitutive dauer formation of *daf-7(−)*, suggesting that DAF-7/TGF-β does not act upstream of mmBCFAs or d17iso-sphingolipid. (**E**) Percentages of *asna-1(−)* animals that reached adulthood on plates with various branched-chain lipid supplements. *asna-1* encodes a protein required for proper DAF-7/TGF-β function and an *asna-1(−)* mutation causes L1 arrest ([@bib33]). Neither C17ISO nor d17iso-SPA permits *asna-1(−)* animals to bypass L1 arrest.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.013](10.7554/eLife.00429.013)10.7554/eLife.00429.014Figure 4---figure supplement 4.Lysosome integrity is not disrupted in mmBCFA-deficient animals.(**A**)--(**H**) DIC and GFP images illustrating *LMP-1::GFP* (**A**--**D**) and *GLO-1::GFP* (**E**--**H**) expression patterns are similar throughout the intestine of young wild-type or *elo-5*(RNAi) larvae. Both *LMP-1::GFP* (**A**--**D**) and *GLO-1::GFP* are lysosomal markers in *C. elegans*. These data indicate that lysosomal integrity is not disrupted in mmBCFA-deficient animals.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.014](10.7554/eLife.00429.014)10.7554/eLife.00429.015Figure 4---figure supplement 5.Neutral red staining of *let-363* -and *elo-5*-deficient animals.(**A**)--(**H**) DIC and Rhodamine channel fluorescence images of larvae stained with Neutral red. (**A**--**D**) *let-363* homozygous L3 animals have increased size and intensity of Neutral red stained lysosomes (**D**) compared to the heterozygous control (**B**). (**E**--**H**) *elo-5* homozygous L1 arrested animals show similar Neutral red intensity and staining pattern (**H**) when compared to the heterozygous control (**F**). These data indicate that (1) lysosome integrity is not disrupted in *elo-5(−)* animals, and (2) unlike *let-363(−)*, *elo-5(−)* animals do not show increased Neutral red staining in the intestine.**DOI:** [http://dx.doi.org/10.7554/eLife.00429.015](10.7554/eLife.00429.015)

The second TORC1-activating transgene used was *raga-1*^*Q63L*^ that has been proven to constitutively activate TORC1 both in mammals and *C. elegans* ([@bib35]; [@bib67]). We found that 50.4% of *elo-5(−)* mutants containing the *raga-1*^*Q63L*^ transgene bypassed L1 arrest and reached L3--L4 stage (n = 248, p=1.0 × 10^−6^; normalized against *elo-5(−/+)* heterozygotes containing the transgene; [Figure 4A](#fig4){ref-type="fig"}) while none of *elo-5(−)* mutants without this transgene did (n = 136). Finally, we also tested a third TORC1-activating transgene, *rheb-1*^*Q71LQ72D*^, and found that it also permitted 41.4% of *elo-5(−)* animals to grow beyond the L1 stage (n = 169; normalized against *elo-5(−/+)* heterozygotes containing the transgene; [Figure 4A](#fig4){ref-type="fig"}). These results led to the conclusion that TORC1 acts downstream of d17iso-GlcCer to promote L1 growth and development and that this activity is negatively regulated by NPRL-2/3.

The mmBCFA/d17iso-GlcCer/TORC1 pathway acts in the intestine to promote postembryonic development {#s2-7}
-------------------------------------------------------------------------------------------------

Previous studies on *elo-5*, *acs-1, tat-2,* and *cgt-1/cgt-3* mutants suggested that biosynthesis and localization of mmBCFAs and their derived sphingolipids in the intestine are essential and sufficient for postembryonic development ([@bib47]; [@bib69]; [@bib38]). The fact that *elo-5(−);nprl-3(ku540)* animals treated with *ife-2* RNAi, that targets intestinal but not neuronal expression of the gene ([@bib74]), are L1 arrested ([Table 1](#tbl1){ref-type="table"}) also points to the requirement of TORC1 activity in the intestine. To directly evaluate a role of intestinal TORC1 in mmBCFA/d17iso-GlcCer regulated growth, we made a *raga-1*^*Q63L*^ TORC1 hyperactivating transgene driven by the intestinal-specific promoter *ges-1* ([@bib15]). We found that *elo-5(−)* animals containing this transgene bypassed the L1 arrest (37.9%, n = 132, normalized against *elo-5(−/+)* heterozygotes containing the transgene; [Figure 4A](#fig4){ref-type="fig"}). The rescue with the intestinal expression was similar to that by a ubiquitously expressed *raga-1*^*Q63L*^ transgene (above). A neuronal-specific *rgef-1* promoter--driven ([@bib9]) *raga-1*^*Q63L*^, however, could not suppress the L1 arrest of *elo-5(−)* animals (0%, n \> 100). These results suggest that the intestinal d17iso-GlcCer/TORC1 pathway regulates postembryonic growth.

Although the genetic data described above sufficiently indicate that TORC1 acts downstream of d17iso-GlcCer and NPRL-2/3 for L1 growth, we carried out further tests to observe downstream activity of TORC1 in the intestine. Because the biochemical assay for p70S6K phosphorylation has not been established in *C. elegans*' TOR-related studies, we adopted the strategy by [@bib70], where localization of FIB-1, a Box C/D small nucleolar ribonucleoprotein (snoRNP) was used as a marker of TORC1 activation in *C. elegans*. In wild-type animals, FIB-1 is highly expressed and localized in the nucleolus, where it methylates pre-rRNAs during ribosome maturation, but the expression is decreased and no longer localized to the nucleolus in *let-363/TOR(−)* animals ([@bib70]). We found that the nucleolar localized FIB-1 was dramatically reduced in intestinal cells of mmBCFA-deficient \[*elo-5(RNAi)*\] animals ([Figure 4C](#fig4){ref-type="fig"}). Furthermore, *nprl-3(−)* rescued the FIB-1 expression and nucleolar localization in *elo-5(−)* back to that of wild type ([Figure 4C](#fig4){ref-type="fig"}). Combining the results from the functional and biochemical assays described above, we conclude that TORC1 is the key downstream factor mediating mmBCFA and d17iso-GlcCer functions in the intestine to promote postembryonic growth and development ([Figure 4D](#fig4){ref-type="fig"}).

Discussion {#s3}
==========

Roles of the mmBCFA/GlcCer/TORC1 pathway in promoting postembryonic development {#s3-1}
-------------------------------------------------------------------------------

In this study, we uncovered and characterized a novel GlcCer-stimulated TORC1 pathway that promotes postembryonic development ([Figure 4D](#fig4){ref-type="fig"}). This discovery reveals a specific link between lipids and the TORC1 signaling pathway. Both ceramide and TORC1 have been individually implicated for roles in stress response, apoptosis, cancers, and other cellular processes by studies in *C. elegans* and mammals ([@bib23]; [@bib24]; [@bib26]; [@bib29]; [@bib39]; [@bib48]; [@bib82]). It is conceivable that some of these functions are mediated by this GlcCer/TORC1 signaling pathway. Moreover, our data suggest that this GlcCer/TORC1 pathway may serve as a 'check point' to coordinate metabolic status in the intestine with postembryonic growth and development. d17iso-GlcCer is a sphingolipid metabolite rather than a nutrient directly absorbed from food ([@bib49]); it is the product of a long biosynthetic pathway involving many enzymatic steps and thus may reflect the availability of many metabolites and enzymes.

Although leucine is a precursor molecule of mmBCFA biosynthesis, this long lipid synthesis pathway is unlikely part of a mechanism to specifically sense the level of essential amino acids. Furthermore, mmBCFA levels are stable in starved L1 larvae ([@bib37]; [Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}), suggesting that mmBCFA levels do not directly reflect the feeding status through a direct substrate--product relationship. There are several reported leucine-sensing mechanisms, based on studies using tissue culture cells ([@bib8]; [@bib14]; [@bib22]; [@bib81]). To test if such a pathway acts in parallel to the mmBCFA/d17iso-GlcCer pathway to promote TORC1 in the *C. elegans* intestine, we supplemented *elo-5(−)* animals with a high level of dietary leucine (10 mM) and failed to observe any suppression of the L1 arrest phenotype ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), consistent with the idea that TORC1 activation by mmBCFA/d17iso-GlcCer is essential in the intestine of L1 larvae and cannot be effectively compensated by another leucine/TORC1 mechanism in *C. elegans*.

In *C. elegans*, both the IIS and DAF-7/TGF-β pathways have been shown to play critical roles in the regulation of postembryonic growth and development in response to nutrient/food availability ([@bib5]; [@bib51]; [@bib18]; [@bib40]; [@bib31]; [@bib72]). Our previous data and this study indicated that the GlcCer/TORC1 pathway is initiated in the intestine ([Figure 4](#fig4){ref-type="fig"}) and is independent of the IIS pathway ([@bib37]). Our additional analysis also suggests that the GlcCer/TORC1 pathway is DAF-7/TGF-β pathway independent ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). This independence may facilitate the role of such a pathway to promote specific developmental events under specific physiological conditions.

The GlcCer/TORC1 signaling pathway is likely conserved in mammals {#s3-2}
-----------------------------------------------------------------

There are several reasons for us to believe that such a GlcCer/TORC1 pathway is likely conserved in mammals. First, the components of TORC1 are conserved between *C. elegans* and mammals. The NPRL-3 protein we identified in this pathway is conserved in all eukaryotes, and its negative regulatory role on TOR has been characterized in budding yeast ([@bib56]). Several proteins (such as NPR2 and IML1) that are reported to form a complex with NPR3 in budding yeast have orthologs in *C. elegans* as well as mammals ([@bib56]; [@bib77]). NPRL2 (human ortholog of NPR2) and DEPDC5 (human ortholog of IML1) have been reported to function as tumor suppressors ([@bib49]; [@bib42]; [@bib56]). This property is consistent with the role of this complex in repressing TOR-mediated growth regulation that was identified in budding yeast and this study. Second, a role for GlcCer in nutrient sensing is consistent with studies showing that ceramide and sphingolipids play roles in cell signaling and growth control in both invertebrates and mammals ([@bib13]; [@bib23]; [@bib48]). The finding that mouse mutants with blocked GlcCer biosynthesis die as early embryos suggests the essential role of these lipids in growth and development ([@bib79]). Third, the TOR pathway is down-regulated by inhibiting the abnormally high GlcCer biosynthesis in polycystic kidney disease in mouse models ([@bib55]), suggesting a possible conserved link between GlcCer and TOR activities.

It is currently unknown whether an iso-branched LCB is also required for the potential role of GlcCer in mammals, given that most LCBs in mammals are straight-chain LCBs. However, it is important to note that mmBCFAs (derived from branched-chain amino acids) are also present in mammals. For example, they are constituents of sphingolipids in skin cells and the intestinal tract of human newborns. They are also found to be incorporated into LCBs (to form an iso- or an anteiso-LCB similar to that in *C. elegans*) in multiple mammalian tissues ([@bib3]; [@bib34]; [@bib59]; [@bib65]). Therefore, their important physiological functions, including possible roles in ceramide-involved growth regulation, may be assumed, albeit not yet uncovered experimentally.

Activation of TORC1 by d17iso-GlcCer {#s3-3}
------------------------------------

How does d17iso-GlcCer regulate the activity of TORC1? Recent work in mammalian cells has indicated that TORC1, for its role in sensing amino acids, localizes at the surface of the lysosome, likely in lipid rafts ([@bib53]). If such a mechanism is conserved in all animals, conceptually, d17iso-GlcCer could act as a ligand that binds to a 'receptor' to either repress the NPRL-2/3 complex or activate the TOR complex at the surface of the lysosome. Alternatively, this lipid could be required for lysosome biogenesis or could be an essential constituent of the membrane microdomain that permits the proper localization or activity of TORC1 on the lysosome. By examining lysosomal markers LMP-1::GFP ([@bib2]; [@bib58]; [@bib64]), GLO-1::GFP ([@bib68]; [@bib80]), and Neutral red ([@bib44]), we did not observe obvious defects in lysosome formation in *elo-5(−)* mutants ([Figure 4---figure supplements 4 and 5](#fig4s4 fig4s5){ref-type="fig"}). Major defects in lysosome formation would also be inconsistent with our genetic suppression data and previous studies on GlcCer by others ([@bib17]; [@bib75]). One possible mechanism is that d17iso-GlcCer acts through the V-ATPase pathway, since the lysosomal V-ATPase has been shown to be stimulated by GlcCer and to play an essential role in TORC1 activation in studies using tissue culture cells ([@bib75]; [@bib82]; [@bib4]). Further biochemical and genetic analyses are needed to test this hypothesis in *C. elegans*.

It may be important to point out again that activation of TORC1 bypasses the robust L1 arrest phenotype caused by either mmBCFA or d17iso-GlcCer deficiency. Remarkably, the *elo-5(−); nprl-3(ku540)* double mutants, still deficient for these lipids, propagate continuously. Therefore, the only essential biochemical role of d17iso-GlcCer might be to activate TORC1 or repress NPRL-3. In other words, the biochemical mechanism underlying this role of d17iso-GlcCer appears to be very specifically connected to TORC1 activation.

Materials and methods {#s4}
=====================

*Caenorhabditis elegans* strains and maintenance {#s4-1}
------------------------------------------------

The following strains were obtained from the Caenorhabditis Genetics Center Database (CGC) or as indicated; wild-type N2 Bristol, *elo-5(gk208), rrf-3(pk1426), daf-3(mgDf90), bra-1(nk1), daf-5(e1386), asna-1(ok938)/hT2\[bli-4(e937)let?(q782)qIs48\], let-363 (ok3018), pwIs50\[lmp-1::GFP + Cbr-unc-119(+)\], hjIs9 \[ges-1p::glo-1::GFP + unc-119(+)\].* The *cgt-1(tm1027)* and *cgt-3(tm504)* mutants were provided by the Mitani Lab (National BioResource Project, Tokyo, Japan). *Caenorhabditis elegans* were maintained at 20°C on NGM plates (referred to as standard plates) with *Escherichia coli* OP50 bacterial food (OP50/NGM). Washes and bleaching were done according to standard protocols ([@bib73]).

Dietary supplements {#s4-2}
-------------------

Fatty acids C13ISO, C17ISO (Larodan), C16:1 n7, C18:1 n7, and C20:4 n6 (Sigma), as well as C17iso-d18:1-Ceramide and d17iso-SPA (custom synthesis; Larodan) were prepared as 10 mM stocks in DMSO. Leucine (Sigma) was prepared as a 100 mM stock in water. A stock solution was mixed with 500 µl of OP50 overnight bacterial suspension in a 1:10 ratio.

Preparation of the C17ISO-deficient eggs and larvae {#s4-3}
---------------------------------------------------

Using *elo-5(gk208)* mutants. *elo-5(gk208)* adults maintained on the plates with *S. maltophlia* ([@bib37]) were washed off in M9 buffer, bleached, and eggs were plated on NGM plates spotted with 300 µl of OP50 overnight liquid culture supplemented with 1 mM C13ISO, which is a less efficient mmBCFA supplement than C17ISO and allows apparent normal growth only in the first generation followed by uniformly arrested C17ISO-deficient L1s in the second generation. Control animals were prepared in the same way, except C17ISO was used as a supplement for the N2 strain instead of *elo-5(gk208).*Using RNAi. Adult animals of the corresponding strains were washed off OP50/NGM plates, bleached, and eggs plated on *elo-5(RNAi)* plates prepared according to the standard protocol. Adults of the next generation were bleached for eggs, producing C17ISO-deficient larvae.

Preparation of C17ISO-deficient late larvae and adults {#s4-4}
------------------------------------------------------

A mixed population of *elo-5(gk208)* mutants maintained on plates with C17ISO supplement, which promoted wild-type growth and proliferation, were collected, washed, and incubated for 1 hr in M9 before replating on OP50/NGM plates without supplement. The next day, animals were washed off and used in the corresponding experiments. Depletion of C17ISO was confirmed by GC analysis of the FA composition in total lipid extracts from a representative group of animals.

Lipid analysis by gas chromatography and mass spectrometry {#s4-5}
----------------------------------------------------------

Gas chromatography method was described in a previous report ([@bib37]). Mass spectrometry sample preparation was described in our previous report ([@bib38]). Briefly, lipid extracts were dissolved in 1 ml of methanol with 1 mM formic acid and subjected to quantitative lipid analysis using a 4000 Q-Trap mass spectrometer (AB Sciex). Samples were infused at a flow rate of 8 μl/min using a Harvard Apparatus syringe pump (Harvard Apparatus). The detailed scan modes are described in the figure legends.

Purification of d17iso-LCB from *Sphingobacterium spiritivorum* {#s4-6}
---------------------------------------------------------------

The *S. spiritivorum* strain was obtained from ATCC (\#33861) and cultured under the conditions suggested by [www.atcc.org](http://www.atcc.org). The total lipids were extracted by the method of [@bib7]. The alkaline stable lipid fraction was purified as described previously ([@bib54]). The hydrolysis of sphingolipids to generate side chain fatty acid and LCB fractions was done as described previously ([@bib54]), with an additional last step using 100% methanol to extract the dry LCB fraction after evaporation of the chloroform solvent. The final fraction of LCB was verified by mass spectrum.

Isolation of *nprl-3(ku540)* through a genetic screen {#s4-7}
-----------------------------------------------------

We performed a screen that was significantly different from our previously published screen that resulted in isolation of three *tat-2(−)* alleles that suppress *elo-5(gk208)* ([@bib69]). The original strain used in this genetic screen was *elo-5(gk208)* injected with *elo-5(genomic rescuing), elo-5Promoter::GFP* ([@bib36]), and *rol-6(dn)* constructs. L4-staged P~0~ animals were mutagenized with standard EMS treatment and then single cloned to 10-cm plates containing 1 mM C13ISO. Suppressor candidates were determined in the F2 generation by the ability to reach gravid adulthood without carrying the GFP or *rol-6* marker and the ability to grow to gravid adulthood without any supplement. From ∼2000 haploid genomes, 4 suppressor candidates were isolated. Among these four, and several suppressor mutations isolated in a previous screen ([@bib69]), only *ku540* permits *elo-5(−)* animals to grow indefinitely without any mmBCFA supplementation and without recovering the production of mmBCFAs.

In our previously published screen ([@bib69]), we isolated three mutations in *tat-2* that can suppress *elo-5(−)*--induced L1 arrest in the presence of C13ISO, or temporarily suppress the L1 arrest for one generation without C13ISO supplement. The hypothesis was that *tat-2(−)* alters the subcellular localization of certain mmBCFA-containing lipids so that their levels (from a slow C13ISO to C17ISO conversion or from maternal sources) are sufficiently maintained for one more generation. Therefore, *tat-2(−)* does not bypass the requirement of mmBCFAs for growth. The *tat-2(−)* mutations were also found to partially and temporarily suppress the lethality associated with disrupting the function of the enzyme (SPTL-1) in the first step of sphingolipid biosynthesis, suggesting a potential link between sphingolipids and mmBCFAs. However, this observation may not be interpreted as the proof that mmBCFAs function through sphingolipids for the following reasons. (1) Unlike feeding d17iso-SPA or the downstream suppressor *nprl-3(ku540)* that fully suppresses mmBCFA deficiency \[*elo-5(−)*\]--induced L1 arrest (this study), *tat-2(−)*does not bypass the requirement of mmBCFAs for growth for more than one generation. (2) *sptl-1(−)* disrupts all sphingolipid biosynthesis and its phenotype is, in contrast to *elo-5(−)*, highly pleiotropic, as animals showed various morphological and growth defects and die at various larval stages. (3) *tat-2* does not exclusively function with mmBCFA-containing lipids; it is also a critical player in steroid metabolism as exemplified by a recent article ([@bib43]). Therefore, the link between mmBCFA and sphingolipids through their interactions with *tat-2* could be indirect and the partial suppression of *sptl-1(−)* by *tat-2(−)* could be due to suppression of mmBCFA-unrelated functions of sphingolipids.

SNP mapping of *ku540* and cloning of the *nprl-3* gene {#s4-8}
-------------------------------------------------------

For SNP mapping of *ku540*, we used a Hawaii strain based *elo-5(gk208)* mutant ([@bib69]) to cross with *elo-5(gk208) ku540* animals and determined the locus of *ku540* by linkage analysis ([@bib12]). The three-point-mapping strain *dpy-13(e184)elo-5(gk208)unc-24(e138)* was also used in this study. The *elo-5(−)ku540* genomic DNA was prepared using the Genomic DNA Sample Preparation Kit (Illumina) and sent for Illumina deep sequencing (High Throughput Next-Generation Sequencing Core, University of Colorado). The raw data was analyzed using Maqgene ([@bib6]), and candidate mutations were confirmed by PCR and sequencing. Homologs of NPRL-2 and NPRL-3 were identified at [ensembl.org](http://ensembl.org). The alignment among NPRL3 homologs was done using MacVector software.

Analysis of *elo-5(gk208) nprl-3(ku540)* double mutants {#s4-9}
-------------------------------------------------------

Except for [Figure 2I](#fig2){ref-type="fig"}, all *elo-5(−) nprl-3(ku540)* animals being tested for [Figure 2](#fig2){ref-type="fig"} were from homozygous mothers. For [Figure 2I](#fig2){ref-type="fig"}, because the control *cgt-3(−);cgt-1(−)* animals were fully arrested at L1 and were derived from *cgt-3(−);cgt-1(−)/nT1\[qIs51\]* heterozygotes, we had to use heterozygous *cgt-3(−);elo-5(−) nprl-3(ku540)/nT1\[qIs51\];cgt-1(−)/nT1\[qIs51\]* P~0~ animals to generate *cgt-1(−);cgt-3(−);elo-5(−) nprl-3(ku540)* homozygous animals to generate comparable data. Because it is difficult to determine the genotype of arrested L1 animals, the ratios of homozygous *cgt-1(−);cgt-3(−);elo-5(−) nprl-3(ku540)* animals that reached adulthood were calculated by the ratio of the homozygous animals in the total adult population, with a normalization by dividing by the expected ratio of 20%, from the Mendelian distribution of strains containing a recessive lethal translocation balancer ([@bib16]).

Generation of *elo-5(−) nprl-3(ku540)* homozygous animals for the tests shown in [Table 1](#tbl1){ref-type="table"} and [Figure 4B](#fig4){ref-type="fig"} is described below.

RNAi analysis by feeding and injection {#s4-10}
--------------------------------------

All RNAi by feeding, except *cgt-3(RNAi)* and *let-363(RNAi)*, used bacterial clones from the MRC RNAi library ([@bib32]) or the ORF-RNAi Library (Open Biosystems) ([Figures 1--3](#fig1 fig2 fig3){ref-type="fig"}). *cgt-3(RNAi)* and *let-363(RNAi)* constructs were made as described ([@bib47]; [@bib28]). Feeding RNAi experiments were done as previously described ([@bib37]). The DNA templates for *nprl-3* and *nprl-2* dsRNA synthesis were amplified from the RNAi-containing bacterial strain (MRC RNAi library) by PCR using T7 primers. dsRNA was synthesized using a MEGAscript RNAi Kit (Life Technologies) and then injected into adults of *elo-5(−)/nT1\[qIs51\], elo-5(-)nprl-3(ku540)/nT1\[qIs51\],* or *cgt-3(-);cgt-1(-)/nT1\[qIs51\]*. The eggs were collected from the 8th to 24th hr after injection. Nongreen F1 adult animals were verified by PCR to confirm the homozygosity of *elo-5(−)* or *cgt-1(−);cgt-3(−)* animals.

Feeding RNAi analysis of TORC1 components and downstream targets {#s4-11}
----------------------------------------------------------------

All RNAi (*raga-1, rheb-1, rsks-1, ife-2*) by feeding used sequence confirmed bacterial clones from both the MRC RNAi library ([@bib32]) or the ORF-RNAi Library (Open Biosystems) ([Table 1](#tbl1){ref-type="table"}). These RNAi clones have been extensively used for TORC1-related studies in many publications/meeting abstracts, and their efficiency and specificity have been well established. Furthermore, results from those references and our experiments have shown RNAi feeding of these genes did not reproduce the strong larval lethal phenotype ([@bib25]; [@bib74]; [@bib41]; [@bib10]; [@bib63]). This difference indicates that TORC1 function is not completely eliminated by RNAi feeding of these genes (*raga-1, rheb-1, rsks-1, ife-2*).

The *elo-5(−) nprl-3(ku540)* animals were balanced by a GFP-labeled *nT1\[qIs51\]* balancer and treated with feeding RNAi. In the next generation, similar to the method described above, the ratios of homozygous *elo-5(−) nprl-3(−)* animals that reached adulthood were calculated by the ratio of homozygous *elo-5(−) nprl-3(−)* animals in the total adult population, with a normalization by dividing by the expected ratio 20%. As reported, RNAi knockdown of TORC1 components and the downstream target genes would affect the normal development of *C. elegans* ([@bib44]; [@bib74]; [@bib82]). In our experiments, the usage of the heterozygous *elo-5(−) nprl-3(ku540)/nT1\[qIs51\]* animals for the RNAi knockdown experiment allowed us to exclude the potential negative effect from RNAi treatment of TORC1 components and TORC1 target genes themselves. Any of those *elo-5(−) nprl-3(−)--*independent negative effects from those RNAi treatments would affect the heterozygous as well as the homozygous *elo-5(−) nprl-3(−)* animals, and therefore not be included in the ratio in the data presented in [Table 1](#tbl1){ref-type="table"}.

Generation of transgenes {#s4-12}
------------------------

For the *pPD95.77-nprl-3*::GFP plasmid, we cloned the potential 1 kbps promoter region upstream of the operon containing *nrpl-3* and inserted it into the pPD95.77 vector ([Figure 4A,B](#fig4){ref-type="fig"}). For *raga-1*^*Q63L*^, the genomic DNA including the full coding region was cloned into pPD95.77, driven by a ubiquitous RPL28 promoter. For *ges-1::raga-1*^*Q63L*^, the genomic DNA including the full coding region was cloned into pPD95.77, driven by an intestinal-specific *ges-1* promoter. For *rheb-1*^*Q71LQ72D*^, the genomic DNA including the full coding region and about 1 kbps of upstream sequence was cloned into pPD95.77. Amino acid mutations in both mutants were introduced by replacement with PCR-generated DNA fragments containing the designed mutations. For *daf-15::rap-1(22)*, the genomic DNA of *daf-15*, including the full coding region and the 1 kbps potential promoter region upstream of *daf-15*, was cloned from the fosmid WRM061cH04. After the stop codon of *daf-15* was removed, it was fused with the genomic DNA encoding the last 22 amino acids and the 3′ UTR of *rap*-*1*. For *pPD95.77-nprl-3*::GFP, 25 ng/μl of plasmid was injected in wild-type animals. For the *daf-15::rap-1(22)* rescue experiment, *elo-5(−)/nT1\[qIs51\]* animals were injected with 10 ng/µl *daf-15::rap-1(22)* and 25 ng/µl *psur-5*::RFP plasmid. In the next generation, the ratios of homozygous *elo-5(−)* animals that reached L3-young adulthood were calculated by the ratio of homozygous *elo-5(−) nprl-3(−)* animals in RFP-positive L3-young adult population, with a normalization by dividing by the expected ratio 20%, as described above. The reason for using heterozygous *elo-5(−)/nT1\[qIs51\]* animals for this experiment is similar to that for the RNAi knockdown experiment we described above. By this method, we exclude the negative effect we observed from constitutively active TORC1 transgenes (*daf-15::rap-1(22), raga-1*^*Q63L*^*, ges-1::raga-1*^*Q63L*^ *or rheb-1*^*Q71LQ72D*^) for their rescue effects.

Neutral red staining {#s4-13}
--------------------

The Neutral red staining was performed following [@bib44]. Animals were fed with Neutral red containing bacteria food for \<10 min before evaluation by microscopy.

Microscopy {#s4-14}
----------

Analysis of GFP expression and phenotypic abnormalities were performed with Nomarski optics using a Zeiss Axioplan2 microscope and a Zeiss AxioCam MRm CCD camera. Plate phenotypes were observed using a Leica MZ16F dissecting microscope, and pictures were taken with a Hamamatsu C4742-95 CCD camera.

Statistical analysis {#s4-15}
--------------------

All statistical analyses, except the dsRNA feeding for TOR-related genes, were performed using Student's *t*-test, and p\<0.05 was considered a significant difference. The Fisher's exact test was used for analysis of the TOR-related dsRNA feeding experiments and *raga-1*^*Q63L*^ rescue experiment, and p\<0.05 was considered a significant difference.
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Detailed description of phenotypes listed in [Figure 1B](#fig1){ref-type="fig"}.
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[^1]: Percentages of *elo-5(−);nprl-3(ku540)* homozygotes with the indicated RNAi treatments that reached adulthood, where *(a)* and *(b)* indicate two different RNAi constructs targeting different parts of the same gene. The presented percentage of *elo-5(−) nprl-3(ku540)* animals that reached adulthood was calculated by normalizing against the percentage of *elo-5(−/+) nprl-3(ku540)*/+ heterozygotes (see 'Materials and methods' for detail). Without C17ISO supplementation, RNAi knockdown of multiple TORC1 components reverted *elo-5(−);nprl-3(ku540)* animals to larval arrest.
